IDH2 and glioblastoma: Glioblastomas, primarily IDH-wild-type tumors, are challenging to treat due to the lack of known risk factors and ineffective pharmacological interventions; however, specific biomarkers like BRAF mutations and gene fusions (e.g., NTRK, FGFR) present potential targeted therapy opportunities [13].